EuBiologics Co., Ltd. Logo

EuBiologics Co., Ltd.

Develops vaccines for global public health and provides biopharmaceutical CRMO services.

206650 | KO

Overview

Corporate Details

ISIN(s):
KR7206650004
LEI:
Country:
South Korea
Address:
서울특별시 강남구 도산대로 509 13층,15층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

EuBiologics Co., Ltd. is a global biopharmaceutical company dedicated to improving public health. The company operates through two primary business segments: Product Development and Contract Research and Manufacturing Organization (CRMO) services. In its product division, EuBiologics develops and supplies safe, effective vaccines for global public health, with a strategic focus on preventing epidemics in developing countries. It is a key global supplier of the WHO-prequalified oral cholera vaccine, Euvichol®. As a CRMO, the company provides specialized, end-to-end services for microbial- and mammalian cell-derived biopharmaceuticals, from cell line development to commercial production. EuBiologics operates advanced bio-manufacturing facilities that comply with international GMP regulations and guidelines, emphasizing technological innovation and adherence to the highest safety and quality standards.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.0 MB
2025-07-31 00:00
Regulatory News Service
투자판단관련주요경영사항 (유티프씨주멀티도즈(수출용) 백신의 한국 품목허가 승인)
Korean 12.0 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]신규시설투자등(자율공시)
Korean 12.7 KB
2025-05-13 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 845.5 KB
2025-05-02 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-04-15 00:00
Regulatory News Service
단일판매ㆍ공급계약체결(자율공시)
Korean 8.9 KB
2025-04-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-04-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.7 KB
2025-03-26 00:00
Board/Management Information
대표이사변경
Korean 10.5 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 18.7 KB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 620.5 KB
2025-03-18 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 255.4 KB

Automate Your Workflow. Get a real-time feed of all EuBiologics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EuBiologics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EuBiologics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.